Sandoz, Lupin To Pay Combined $6.7M In Pay-For-Delay MDL
Law360, Los Angeles (April 4, 2017, 9:29 PM EDT) -- Sandoz Inc. and Lupin Ltd. have agreed to pay a combined $6.7 million to exit multidistrict litigation accusing them of striking a deal with a Valeant Pharmaceuticals Corp. unit to delay launching their generic versions of the acne medication Solodyn, according to a pair of proposed deals Tuesday.
The settlements, if approved, would release the two generics makers from litigation brought by direct buyers of the drug, as well as consumers who said the companies colluded with Medicis Pharmaceutical Corp. to limit Solodyn's competition, in turn keeping the drug's price high, according to court filings.
Sandoz will pay $1.8 million to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!